NCT04836221
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must identify as African American; Patients must have blood pressure that is greater than or equal to 120/80 OR must have a diagnosis of diabetes as a result of initiating steroid-containing chemotherapy or targeted PI3K inhibitor therapies (e.g., alpelisib/Piqray)
Exclusions: 
https://ClinicalTrials.gov/show/NCT04836221